# CareRx Corporation (CRRX.TO) fundamentals

Data as of 2026-11-04. TSX, Canada. Sector: Healthcare / Health Care Providers. Price C$3.36, market value C$213 million.

## Valuation
- **P/E (trailing): 8.2×** (5-yr avg 9.2×, 3-yr avg 9.2×). CareRx Corporation trades at 8.2× trailing earnings, close to its own five-year average of 9.2×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 11.2×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.02**. A PEG of 0.02 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.6×**. Each dollar of revenue is priced at 0.6×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 9.3×**. Enterprise value is 9.3× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 10.7%** (5-yr avg 12.3%). Free cash flow equals 10.7% of the market value, in line with its five-year average of 12.3%. Above 5% is generally attractive.
- **Earnings yield: 12.2%**. The inverse of the P/E: 12.2% of the price is earned each year.

## Profitability
- **Gross margin: 26.4%**. CareRx Corporation keeps 26.4% of revenue after the direct cost of what it sells.
- **Operating margin: 3.4%**. 3.4% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 7.1%**. 7.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 23.9%**. 23.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 7.4%**. Return on all capital, debt included, is 7.4%.
- **Return on assets: 10.6%**. Each dollar of assets produces 10.6% of profit.

## Growth
- **Revenue growth (1 yr): 1.0%** (3-yr -1.0%/yr, 5-yr 17.9%/yr). Revenue grew 1.0% over the last year, against 17.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 648.9%**. Earnings per share rose 648.9%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 36.0%/yr**. Free cash flow has compounded at 36.0% a year over three years.

## Financial health
- **Debt to equity: 0.71**. Debt is 0.71 times equity, moderate leverage.
- **Net debt / EBITDA: 2.1×**. It would take 2.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 2.0×**. Operating profit covers interest 2.0×, thin but manageable.
- **Current ratio: 1.06** (quick 0.78). Current assets cover the next year's liabilities 1.06 times.
- **Altman Z-score: 3.14**. A Z-score of 3.14 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.62%** (C$0.08 per share, trailing). CareRx Corporation yields 2.62%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 5%** (11% of free cash flow). 5% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 1**. 1 straight year of increases.
- **Shareholder yield: 3.6%**. Dividends plus net buybacks return 3.6% of the market value a year.

## Price and momentum
- **Total return (1 yr): -4.3%** (YTD -10.8%, 3-mo -7.2%). The shares are down 4.3% over twelve months including dividends.
- **From 52-week high: -16.0%** (8.4% above the low). Trading 16% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 0.12** (volatility 28%). Beta of 0.12 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CRRX.TO · Page: https://foliofundamentals.com/stocks/crrx.to

Not investment advice.